These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 24922685)

  • 41. Impact of interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer on surgical and oncologic outcome.
    Zeng WG; Zhou ZX; Liang JW; Wang Z; Hou HR; Zhou HT; Zhang XM; Hu JJ
    J Surg Oncol; 2014 Sep; 110(4):463-7. PubMed ID: 24889826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
    Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
    Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
    Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
    Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
    Kim CW; Yu CS; Yang SS; Kim KH; Yoon YS; Yoon SN; Lim SB; Kim JC
    Ann Surg Oncol; 2011 Nov; 18(12):3271-7. PubMed ID: 21537868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer.
    Huh JW; Kim HR; Kim YJ
    Dis Colon Rectum; 2013 Jun; 56(6):698-703. PubMed ID: 23652742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer.
    Lu JY; Xiao Y; Qiu HZ; Wu B; Lin GL; Xu L; Zhang GN; Hu K
    J Surg Oncol; 2013 Sep; 108(4):213-9. PubMed ID: 23913795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
    Leibold T; Akhurst TJ; Chessin DB; Yeung HW; Macapinlac H; Shia J; Minsky BD; Saltz LB; Riedel E; Mazumdar M; Paty PB; Weiser MR; Wong WD; Larson SM; Guillem JG
    Ann Surg Oncol; 2011 Oct; 18(10):2783-9. PubMed ID: 21476107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients.
    Box B; Lindsey I; Wheeler JM; Warren BF; Cunningham C; George BD; Mortensen NJ; Jones AC
    Dis Colon Rectum; 2005 Jun; 48(6):1153-60. PubMed ID: 15868236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transanal local excision for distal rectal cancer and incomplete response to neoadjuvant chemoradiation - does baseline staging matter?
    Perez RO; Habr-Gama A; São Julião GP; Proscurshim I; Coelho AQ; Figueiredo MN; Fernandez LM; Gama-Rodrigues J
    Dis Colon Rectum; 2014 Nov; 57(11):1253-9. PubMed ID: 25285691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation.
    Wolthuis AM; Penninckx F; Haustermans K; Ectors N; Van Cutsem E; D'Hoore A
    Ann Surg Oncol; 2011 Mar; 18(3):684-90. PubMed ID: 20842458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy.
    Pacelli F; Tortorelli AP; Rosa F; Bossola M; Sanchez AM; Papa V; Valentini V; Doglietto GB
    Ann Surg Oncol; 2010 Jan; 17(1):152-62. PubMed ID: 19834766
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study.
    Madbouly KM; Abbas KS; Hussein AM
    Am J Surg; 2014 Jun; 207(6):824-31. PubMed ID: 24112666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer?
    Tranchart H; Lefèvre JH; Svrcek M; Flejou JF; Tiret E; Parc Y
    Ann Surg Oncol; 2013 May; 20(5):1551-9. PubMed ID: 23188545
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
    Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
    Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.
    Oh HK; Kang SB; Lee SM; Lee SY; Ihn MH; Kim DW; Park JH; Kim YH; Lee KH; Kim JS; Kim JW; Kim JH; Chang TY; Park SC; Sohn DK; Oh JH; Park JW; Ryoo SB; Jeong SY; Park KJ
    Ann Surg Oncol; 2014 Jul; 21(7):2280-7. PubMed ID: 24604580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer.
    Ebara T; Kaira K; Saito J; Shioya M; Asao T; Takahashi T; Sakurai H; Kanai Y; Kuwano H; Nakano T
    Anticancer Res; 2010 Oct; 30(10):4223-7. PubMed ID: 21036745
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Combined treatment of patients with locally advanced rectal cancer].
    Berdov BA; Erygin DV; Nevol'skikh AA; Titova LN; Zamulaeva IA; Kondrashova LM
    Vopr Onkol; 2014; 60(4):497-503. PubMed ID: 25552072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study.
    Wang LW; Hsiao CF; Chen WT; Lee HH; Lin TC; Chen HC; Chen HH; Chien CR; Lin TY; Liu TW
    J Surg Oncol; 2014 May; 109(6):580-5. PubMed ID: 24374744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.